This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Sanofi Pasteur MSD Limited

Mallards Reach, Bridge Avenue, Maidenhead, Berkshire, SL6 1QP
Telephone: +44 (0)1628 785 291
Fax: +44 (0)1628 671 722
Medical Information Direct Line: +44 (0)1628 587 693
Medical Information e-mail: medinfo@spmsd.com
Medical Information Fax: +44 (0)1628 635 072

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 17/10/2012
SPC PEDIACEL


Go to top of the page
1. Name of the medicinal product

PEDIACEL, suspension for injection in a vial

Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)


Go to top of the page
2. Qualitative and quantitative composition

Each 0.5 mL dose contains:

Diphtheria Toxoid1

not less than 30 IU

Tetanus Toxoid1

not less than 40 IU

Acellular Pertussis Antigens1

Pertussis Toxoid (PT)

20 micrograms

Filamentous Haemagglutinin (FHA)

20 micrograms

Pertactin (PRN)

3 micrograms

Fimbriae Types 2 and 3 (FIM)

5 micrograms

Poliovirus (Inactivated)2

Type 1 (Mahoney)

40 D antigen units3

Type 2 (MEF-1)

8 D antigen units3

Type 3 (Saukett)

32 D antigen units3

Haemophilus influenzae Type b Polysaccharide

(Polyribosylribitol Phosphate)

10 micrograms

Conjugated to Tetanus Toxoid (PRP-T)

20 micrograms

1 adsorbed on aluminium phosphate

1.5 mg

(0.33 mg aluminium)

 

2 Produced in Vero cells.

 

3 or equivalent antigenic quantity determined by a suitable immunochemical method.

For a full list of excipients, see section 6.1.


Go to top of the page
3. Pharmaceutical form

Suspension for injection in a vial

PEDIACEL is a uniform, cloudy, white to off-white suspension.


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

PEDIACEL is indicated for primary and booster vaccination against diphtheria, tetanus, pertussis, poliomyelitis and invasive Haemophilus influenzae type b disease in infants and children from the age of 6 weeks up to the fourth birthday. PEDIACEL should be used in accordance with applicable official recommendations.


Go to top of the page
4.2 Posology and method of administration

Posology

Paediatric population

Primary Vaccination

The primary vaccination series consists of 2 or 3 doses of 0.5 mL and may be commenced from 6 weeks of age according to applicable official recommendations. There should be an interval of at least one month between doses.

Booster Vaccination

After primary series vaccination with either 2 doses (e.g., 3, 5 months) or 3 doses (e.g., 2, 3, 4 months) of PEDIACEL, a booster dose should be given at least 6 months after the last priming dose in accordance with applicable official recommendations.

PEDIACEL can be considered for the booster if the composition is in accordance with the applicable official recommendations.

Based on safety and immunogenicity data from clinical studies, PEDIACEL should preferably be given to children who received the same vaccine in infancy. However, PEDIACEL may be given as a booster to children who received other diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) with or without hepatitis B vaccines in their primary series.

Children less than 6 weeks of age: The safety and efficacy of PEDIACEL in children less than 6 weeks of age has not been established. No data are available

Children 4 years of age or older: The safety and efficacy of PEDIACEL in children 4 years of age or older has not been established. No data are available

Method of administration

PEDIACEL should be administered intramuscularly. The recommended injection sites are the anterolateral aspect of the thigh or the deltoid region of the upper arm if there is adequate muscle mass, according to local clinical practice recommendations. The anterolateral aspect of the thigh is the preferred site for infants under one year of age.

Do not administer PEDIACEL by intravascular injection; ensure that the needle does not penetrate a blood vessel. Do not administer subcutaneously.

Precautions to be taken before handling or administering the medicinal product

For instructions for preparation of the medicinal product before administration, see section 6.6.


Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 or to any residual substances carried over from manufacture (neomycin, streptomycin, polymyxin B, glutaraldehyde, formaldehyde and bovine serum albumin), which may be present in undetectable trace amounts.

PEDIACEL is contraindicated if the infant has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis containing vaccine. In these circumstances pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria, tetanus, polio and Hib vaccines.

PEDIACEL is contraindicated in infants with a progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy. Pertussis vaccine should not be administered to children with such conditions until a treatment regimen has been established and the condition has stabilized.

As with other vaccines, administration of PEDIACEL should be postponed in children suffering from acute severe febrile illness. The presence of a minor infection (e.g., mild upper respiratory infection) is not a contraindication.


Go to top of the page
4.4 Special warnings and precautions for use

Applicable official recommendations for childhood immunizations should be consulted before administering this vaccine to children in or after the second year of life since the exact combination of antigens may not be considered appropriate and/or necessary after completion of the primary vaccination series.

Prior to immunization

As with all injectable vaccines, appropriate medical treatment and supervision should be readily available for immediate use in case of a rare anaphylactic reaction following the administration of the vaccine (see section 4.8).

If any of the following events have occurred after administration of a pertussis-containing vaccine, the decision to administer PEDIACEL should be based on careful consideration of potential benefits and possible risks.

• Temperature of ≥40°C within 48 hours, not attributable to another identifiable cause

• Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours

• Persistent crying lasting ≥3 hours within 48 hours

• Convulsions with or without fever within 3 days.

If Guillain-Barré syndrome or brachial neuritis has occurred following receipt of prior vaccine containing tetanus toxoid, the decision to give any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks.

A history of febrile convulsions, a family history of convulsions or Sudden infant death syndrome (SIDS) do not constitute a contraindication for the use of PEDIACEL. Vaccinees with a history of febrile convulsions should be closely followed up as such adverse events may occur within 2 to 3 days post vaccination.

The potential risk of apnoea and the need for respiratory monitoring for 48-72 hours should be considered when administering the primary immunization series to very premature infants (born ≤28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

Immunocompromised children (whether from disease or treatment) may not obtain the expected immune response. If possible, consideration should be given to delaying vaccination until after the completion of any immunosuppressive treatment. HIV infection is not considered as a contraindication. The expected immunological response may not be obtained after vaccination of immunosuppressed patients.

Administration precautions

As for all injectable products, the vaccine should be administered with caution to children with thrombocytopenia or bleeding disorders since bleeding may occur following an intramuscular injection.

Other considerations

As with any vaccine, a protective immune response may not be elicited in all vaccinees (see section 5.1).

Vaccines that contain Hib antigen do not provide protection against infections caused by other types of Haemophilus influenzae or against meningitis of other origin.

Granuloma or sterile abscess at the injection site has been reported with vaccines containing aluminum.

Since the Hib capsular polysaccharide antigen is excreted in the urine, a positive urine test can be observed within 1-2 weeks following vaccination. Other tests should be performed in order to confirm Hib infection during this period.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Concomitant vaccine administration

PEDIACEL may be administered at the same time as, but as a separate injection to, any of the following monovalent or combination vaccines: hepatitis B, 7-valent pneumococcal conjugate, measles, mumps and rubella (MMR), varicella or meningococcal group C conjugate vaccines. Injections should be made into separate sites and, preferably, into separate limbs.

Meningococcal Group C Conjugate Vaccines

In a controlled clinical study PEDIACEL was administered concomitantly with two different meningococcal group C conjugate vaccines (a meningococcal group C CRM197 conjugate and a meningococcal group C tetanus toxoid conjugate vaccine) at 2, 3 and 4 months of age.Although seroprotection rates were high in both groups (>88.0% anti-PRP ≥0.15 micrograms/mL), antibody responses to the Hib component of PEDIACEL (PRP conjugated to tetanus toxoid) were lower when co-administered with a meningococcal group C CRM197 conjugate vaccine than with a meningococcal group C tetanus toxoid conjugate vaccine. PEDIACEL did not affect the proportions of infants with meningococcal group C serum bactericidal antibody (SBA) titres of at least 1:8 (measured with rabbit complement) when co-administered with either a CRM197 conjugate or a tetanus toxoid conjugate vaccine. (See section 5.1)

Vaccine drug interactions

Immunosuppressive treatments may interfere with the development of the expected immune response. (See section 4.4)


Go to top of the page
4.6 Fertility, pregnancy and lactation

Not applicable. This vaccine is not intended for administration to women of child-bearing age.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not relevant.


Go to top of the page
4.8 Undesirable effects

a. Summary of the Safety Profile

The data from 11 clinical trials conducted in several countries and using various immunization schedules were pooled. In these studies, PEDIACEL was administered in a primary series (N = 1487) and as a booster dose (N = 1632). The adverse reactions occurring after vaccination are summarised in Table 1 below.

The most frequently reported adverse reactions after PEDIACEL administration were decreased activity, injection site reactions (tenderness, erythema, swelling), pyrexia (≥38°C), vomiting, abnormal crying, appetite loss, and irritability.

Adverse reactions spontaneously reported following the commercial use of PEDIACEL are also summarised in Table 1 below. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.

b. Tabulated list of adverse reactions

Adverse reactions are ranked under headings of frequency using the following convention:

Very common

(≥1/10)

Common

(≥1/100 to <1/10)

Uncommon

(≥1/1,000 to <1/100)

Rare

(≥1/10,000 to <1/1,000)

Very Rare

(<1/10,000), including individual cases

Not known:

cannot be estimated from available data.

Table 1: List of Adverse Events

Adverse Reactions

Frequency

Immune System Disorders

Hypersensitivity

Not known

Anaphylactic reaction (such as urticaria, angioedema).

Metabolism and Nutrition Disorders

Appetite loss

Very common

Psychiatric Disorders

Irritability

Very common

Abnormal crying

Very common

Nervous System Disorders

Convulsion (with or without fever)

Uncommon

High-pitched crying

Not known

*Hypotonic hyporesponsive episode (infant appears pale, hypotonic (limp) and unresponsive).

Somnolence

Vascular Disorders

Pallor

Not known

Respiratory, Thoracic and Mediastinal Disorders

Apnoea

Not known

Gastrointestinal Disorders

Vomiting

Very common

Diarrhoea

Common

Skin and Subcutaneous Tissue Disorders

Rash

Not known

Musculoskeletal, Connective Tissue and Bone Disorders

Pain in vaccinated limb

Not known

General Disorders and Administration Site Conditions

Decreased activity

Very common

Injection site tenderness

Injection site erythema

Pyrexia (≥38°C),

Injection site swelling

Injection site bleeding

Common

Injection site bruising

Extensive limb swelling (from the injection site beyond one or both joints)

Uncommon

Pyrexia (>40.5°C),

Not known

Injection site mass

Asthenia

Listlessness

Edematous reactions affecting one or both lower limbs

* To date, this condition has not been associated with any permanent sequelae.

c. Description of Selected Adverse Events

Edematous reactions affecting one or both lower limbs have occurred following vaccination with H. influenzae type b containing vaccines. When this reaction occurs, it does so mainly after primary injections and is observed within the first few hours following vaccination. Associated symptoms may include cyanosis, redness, transient purpura and severe crying. All events resolved spontaneously without sequelae within 24 hours.

d. Other Special Populations

Apnoea in very premature infants (≤28 weeks of gestation). (See section 4.4)


Go to top of the page
4.9 Overdose

Not applicable.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Bacterial and viral vaccines combined, diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus, ATC code J07CA06.

Immunogenicity

In a randomized, single-blind, controlled multi-centre clinical trial, the immunogenicity of PEDIACEL was compared to another DTaP-IPV+Hib vaccine when administered to infants using the three-dose primary immunization schedule of 2, 3 and 4 months with a booster dose given at 12-18 months. Antibody responses one month after completion of the three-dose primary series and one month after the booster dose of PEDIACEL are summarized below.

Table 2: Immune Responses

Antigen

Criteria

PEDIACEL

Post-dose 3

N = 248

PEDIACEL

Post-dose 4

N = 220

Diphtheria

≥0.01 IU/mL

≥0.1 IU/mL

99.2%

39.3%

--

99.1%

Tetanus

≥0.01 IU/mL

≥0.1 IU/mL

100.0%

99.2%

--

100.0%

Pertussis

Pertussis Toxoid

Filamentous Haemagglutinin

Pertactin

Fimbriae Types 2 and 3

 

seroresponse*

seroresponse†

seroresponse*

seroresponse*

 

98.7%

93.2%

87.5%

95.8%

 

96.7%

83.2%

86.9%

95.7%

Polio

Type 1

Type 2

Type 3

 

≥1:8 Dilution

≥1:8 Dilution

≥1:8 Dilution

 

100.0%

99.2%

99.6%

 

99.5%

99.5%

99.5%

Haemophilus influenzae type b

 

PRP

≥0.15 micrograms/mL

≥1.0 micrograms/mL

91.0%

 

63.3%

--

 

99.1%

* Post-dose 3 ≥ EU/mL if pre-dose 1 <4 EU/mL or post-dose 3 ≥pre-dose 1 if pre-dose 1 ≥ EU/mL.

Four-fold rise from pre-dose 4 if pre-dose 4 <4 x 4 EU/mL or two-fold rise from pre-dose 4 ≥4 x 4 EU/mL.

† Post-dose 3 ≥EU/mL if pre-dose 1 <3 EU/mL or post-dose 3 ≥pre-dose 1 if pre-dose 1 ≥ EU/mL.

Four-fold rise from pre-dose 4 if pre-dose 4 <4 x 3 EU/mL or two-fold rise from pre-dose 4 if pre-dose 4 ≥4 x 3 EU/mL.

In a controlled clinical trial, the immunogenicity of booster vaccination with PEDIACEL was compared to a hexavalent DTaP-IPV-Hib-Hepatitis B vaccine given at 11 to 18 months of age in toddlers who had been primed with 3 doses of DTaP-IPV-Hib-Hepatitis B vaccine. 100% of participants receiving PEDIACEL achieved seroprotective levels for diphtheria and tetanus (≥0.1 IU/mL), PRP (≥1.0 micrograms/mL) and all three types of polio (≥1:8 dilution). The booster response rates for pertussis antigens PT, FHA, PRN and FIM were 90.4%, 86.7%, 95.9% and 26.4%. This was the first dose containing FIM for these participants.

In a randomized, double-blind, controlled clinical trial, the immunogenicity of PEDIACEL was compared to another DTaP-IPV+Hib vaccine when administered to infants using the two-dose primary immunization schedule of 3 and 5 months followed by a booster dose at 12 months. Antibody responses one month after completion of the three-dose series are summarized below.

Table 3: Immune Response

Antigen

Criteria

PEDIACEL

Post-dose 3

N = 325

Diphtheria

≥0.01 IU/mL

≥0.1 IU/mL

98.2%

95.1%

Tetanus

≥0.01 IU/mL

≥0.1 IU/mL

100.0%

100.0%

Pertussis

Pertussis Toxoid

Filamentous Haemagglutinin

Pertactin

Fimbriae Types 2 and 3

 

seroresponse*

seroresponse†

seroresponse*

seroresponse*

 

98.5%

99.1%

96.9%

96.3%

Polio

Type 1

Type 2

Type 3

 

≥1:8 Dilution

≥1:8 Dilution

≥1:8 Dilution

 

99.4%

99.7%

98.8%

Haemophilus influenzae type b

PRP

≥0.15 micrograms/mL

≥1.0 micrograms/mL

99.1%

93.2%

* Post-dose 3 ≥4 EU/mL if pre-dose 1 <4 EU/mL or post-dose 3 ≥pre-dose 1 if pre-dose 1 ≥4 EU/mL.

† Post-dose 3 ≥3 EU/mL if pre-dose 1 <3 EU/mL or post-dose 3 ≥pre-dose 1 if pre-dose 1 ≥3 EU/mL.

Pertussis efficacy

In a clinical trial in Sweden (Sweden I Efficacy Trial), the pertussis components in PEDIACEL (i.e., PT, FHA, PRN and FIM) have been shown to prevent pertussis in infants with a protective efficacy of 85.2% using the WHO case definition (≥21 consecutive days of paroxysmal cough with culture or serologic confirmation or epidemiological link to a confirmed case). In the same study, the protective efficacy against mild disease (≥1 day of paroxysmal cough with culture or serologic confirmation) was 77.9%. In a controlled clinical trial in Sweden (Sweden II Trial), a DTaP vaccine with the same formulation of pertussis antigens as PEDIACEL demonstrated protection against pertussis with any cough.


Go to top of the page
5.2 Pharmacokinetic properties

Not applicable.


Go to top of the page
5.3 Preclinical safety data

Limited pre-clinical testing of PEDIACEL and closely related products revealed no unexpected findings and no target organ toxicity.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Phenoxyethanol

Polysorbate 80

Water for Injections


Go to top of the page
6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.


Go to top of the page
6.3 Shelf life

4 years.


Go to top of the page
6.4 Special precautions for storage

Store in a refrigerator (2°C - 8°C). Do not freeze. Keep the container in the outer carton in order to protect from light.


Go to top of the page
6.5 Nature and contents of container

0.5 ml suspension for injection in vial (glass) with stopper (bromobutyl) pack size of 1 or 10

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

Instructions for use

The vaccine should be used as supplied; no dilution or reconstitution is necessary.

Inspect for extraneous particulate matter and/or discolouration before use. If these conditions exist, the product should not be administered.

Shake the vial well to uniformly distribute the suspension immediately before administering the vaccine. The normal appearance of the vaccine is a uniform, cloudy, white to off-white suspension, which may sediment during storage.

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.


Go to top of the page
7. Marketing authorisation holder

Sanofi Pasteur MSD Ltd

Mallards Reach

Bridge Avenue

Maidenhead

Berkshire, SL6 1QP

UK


Go to top of the page
8. Marketing authorisation number(s)

PL 06745/0120


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

16-10-2002 / 15-10-2007


Go to top of the page
10. Date of revision of the text

Product information as of 08/2012



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/15257/SPC/